Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CNTX 
Context Therapeutics Inc (CNTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/02/2025: CNTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.4
1 Year Target Price $5.4
| 2 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -5.76% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 56.29M USD | Price to earnings Ratio - | 1Y Target Price 5.4 |
Price to earnings Ratio - | 1Y Target Price 5.4 | ||
Volume (30-day avg) 5 | Beta 1.86 | 52 Weeks Range 0.49 - 2.75 | Updated Date 07/1/2025 |
52 Weeks Range 0.49 - 2.75 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.28 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -38.01% | Return on Equity (TTM) -55.59% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -30384334 | Price to Sales(TTM) - |
Enterprise Value -30384334 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.6 | Shares Outstanding 89704200 | Shares Floating 39385523 |
Shares Outstanding 89704200 | Shares Floating 39385523 | ||
Percent Insiders 2.33 | Percent Institutions 79.93 |
Upturn AI SWOT
Context Therapeutics Inc
Company Overview
History and Background
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hormone-driven cancers. Founded in 2015, the company's primary focus is on developing therapies targeting progesterone receptor positive (PR+) tumors. They have gone through several funding rounds and clinical trial phases.
Core Business Areas
- Onapristone Extended Release (ONA-XR): ONA-XR is Context Therapeutics' lead product candidate, an oral selective progesterone receptor (PR) antagonist, designed to treat PR+ cancers, with a focus on ovarian, endometrial and breast cancers. It's designed to block progesterone's activation of its receptor, which can lead to cancer cell growth.
- CTX-351: CTX-351 is an antibody-drug conjugate (ADC) targeting Claudin 6 (CLDN6). It is in development for CLDN6-expressing tumors.
Leadership and Structure
Martin Lehr is the CEO. The company operates with a typical biopharmaceutical structure, including research and development, clinical operations, and corporate functions. It has a board of directors that oversees the company's strategy and governance.
Top Products and Market Share
Key Offerings
- Onapristone Extended Release (ONA-XR): ONA-XR is in clinical development for the treatment of progesterone receptor positive cancers, including ovarian, endometrial, and breast cancer. Currently, there is no market share as it is still in development. Competitors depend on the specific cancer being targeted. For example, competitors in ovarian cancer treatment include companies developing PARP inhibitors (e.g., AstraZeneca, GSK) and chemotherapies (various generic manufacturers).
- CTX-351: CTX-351 is an antibody-drug conjugate (ADC) targeting Claudin 6 (CLDN6). It is in development for CLDN6-expressing tumors. Currently, there is no market share as it is still in development. Competitors would include companies developing other ADCs or targeted therapies for CLDN6-expressing cancers. For example, BioNTech is a potential competitor.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive. It's characterized by long development timelines, high costs, and significant regulatory hurdles. There's a growing focus on targeted therapies and personalized medicine, reflecting increasing understanding of cancer biology.
Positioning
Context Therapeutics is positioned as a company specializing in PR+ cancer therapies and Claudin 6 expressing tumors. Its competitive advantage lies in its targeted approach and potential to address unmet needs in specific patient populations.
Total Addressable Market (TAM)
The TAM for ovarian, endometrial, and breast cancers is substantial, potentially reaching billions of dollars annually. The TAM for CTX-351 depends on the prevalence of CLDN6 expressing cancers. Context Therapeutics aims to capture a portion of this market by providing more targeted and effective treatments than current standards of care.
Upturn SWOT Analysis
Strengths
- Targeted therapy approach
- Lead candidate addresses unmet needs in PR+ cancers
- Experienced management team
- Proprietary drug development platform
Weaknesses
- Clinical trial risks
- High cash burn rate
- Reliance on external funding
- Small market capitalization
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Favorable regulatory environment
Threats
- Competition from established therapies
- Clinical trial failures
- Regulatory hurdles
- Patent expirations
- Economic downturn affecting funding
Competitors and Market Share
Key Competitors
- AZN
- GSK
- BNTX
- MRK
Competitive Landscape
Context Therapeutics competes with both established pharmaceutical companies and other biotechnology firms developing therapies for cancer. Its competitive advantage lies in its focus on specific tumor subtypes and its targeted approach. It faces challenges related to clinical trial risks and funding.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is reflected in the company's progress in advancing its drug candidates through clinical trials and securing funding.
Future Projections: Future growth depends on the success of ongoing clinical trials, regulatory approvals, and commercialization efforts. Analyst projections should be located online.
Recent Initiatives: Recent initiatives include advancing ONA-XR and CTX-351 through clinical trials and exploring potential partnerships.
Summary
Context Therapeutics is a clinical-stage biopharmaceutical company focusing on targeted cancer therapies with a focus on PR+ cancers. ONA-XR, the lead product, is in the clinical trial stage. Positive clinical results could be significant drivers of value. However, the company is exposed to the inherent risks of clinical trials and needs to secure ongoing funding.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Context Therapeutics Inc
Exchange NASDAQ | Headquaters Philadelphia, PA, United States | ||
IPO Launch date 2021-10-20 | Co-Founder, President, CEO & Director Mr. Martin A. Lehr | ||
Sector Healthcare | Industry Biotechnology | Full time employees 12 | |
Full time employees 12 | |||
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.